ECM
PACB icon

EMC Capital Management’s Pacific Biosciences PACB Stock Holding History

EMC Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,785
Closed -$18K – 349
2025
Q1 		$18K Hold
14,785
– – 0.01% 270
2024
Q4 		$27K Buy
14,785
+954
+7% +$1.86K 0.02% 262
2024
Q3 		$265K Sell
13,831
-43,654
-76% -$71.7K 0.17% 115
2024
Q2 		$68K Buy
57,485
+24,785
+76% +$50.1K 0.04% 252
2024
Q1 		$114K Buy
32,700
+20,100
+160% +$118K 0.07% 230
2023
Q4 		$124K Sell
12,600
-3,000
-19% -$24.5K 0.08% 201
2023
Q3 		$126K Buy
15,600
+10,251
+192% +$117K 0.09% 193
2023
Q2 		$86 Sell
5,349
-2,851
-35% -$34.6K 0.07% 230
2023
Q1 		$92K Buy
8,200
+6,000
+273% +$59.7K 0.08% 228
2022
Q4 		$18K Buy
2,200
+1,000
+83% +$8.62K 0.02% 283
2022
Q3 		$12K Buy
+1,200
New +$6.88K 0.01% 269

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EMC Capital Management's PACB Position: Q2 2025 in Review

EMC Capital Management sold out of Pacific Biosciences (PACB) in Q2 2025, closing a stake of 14,785 shares — an estimated $18K sold.

EMC Capital Management first reported a position in PACB in Q3 2022 and held it in 11 quarters. The position peaked at $265K in Q3 2024. 207 funds tracked by Wall St. Rank hold PACB as of Q2 2025.

  • EMC Capital Management reported no remaining Pacific Biosciences position as of Q2 2025 after selling out during the quarter.
  • EMC Capital Management sold 14,785 Pacific Biosciences shares in Q2 2025, an estimated $18K.
  • EMC Capital Management first reported a position in Pacific Biosciences in Q3 2022 and held it in 11 quarters.
  • EMC Capital Management's Pacific Biosciences position peaked at $265K in Q3 2024.
  • 207 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2025.

Based on EMC Capital Management's 13F filing for Q2 2025, filed 11 Aug 2025.